Unknown

Dataset Information

0

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.


ABSTRACT: Induction of potent immune responses to self-antigens remains a major challenge in tumor immunology. We have shown that a vaccine based on alphavirus replicon particles (VRP) activates strong cellular and humoral immunity to tyrosinase-related protein-2 (TRP2) melanoma antigen, providing prophylactic and therapeutic effects in stringent mouse models. Here, we report that the immunogenicity and efficacy of this vaccine is increased in combination with either antagonist anti-CTL antigen-4 (CTLA-4) or agonist anti-glucocorticoid-induced TNF family-related gene (GITR) immunomodulatory monoclonal antibodies (mAb). In the challenging therapeutic setting, VRP-TRP2 plus anti-GITR or anti-CTLA-4 mAb induced complete tumor regression in 90% and 50% of mice, respectively. These mAbs had similar adjuvant effects in priming an adaptive immune response against the vaccine-encoded antigen, augmenting, respectively, approximately 4- and 2-fold the TRP2-specific CD8(+) T-cell response and circulating Abs, compared with the vaccine alone. Furthermore, while both mAbs increased the frequency of tumor-infiltrating CD8(+) T cells, anti-CTLA-4 mAb also increased the quantity of intratumor CD4(+)Foxp3(-) T cells expressing the negative costimulatory molecule programmed death-1 (PD-1). Concurrent GITR expression on these cells suggests that they might be controlled by anti-GITR mAbs, thus potentially explaining their differential accumulation under the two treatment conditions. These findings indicate that combining immunomodulatory mAbs with alphavirus-based anticancer vaccines can provide therapeutic antitumor immune responses in a stringent mouse model, suggesting potential utility in clinical trials. They also indicate that tumor-infiltrating CD4(+)Foxp3(-)PD-1(+) T cells may affect the outcome of immunomodulatory treatments.

SUBMITTER: Avogadri F 

PROVIDER: S-EPMC4406637 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.

Avogadri Francesca F   Zappasodi Roberta R   Yang Arvin A   Budhu Sadna S   Malandro Nicole N   Hirschhorn-Cymerman Daniel D   Tiwari Shakuntala S   Maughan Maureen F MF   Olmsted Robert R   Wolchok Jedd D JD   Merghoub Taha T  

Cancer immunology research 20140226 5


Induction of potent immune responses to self-antigens remains a major challenge in tumor immunology. We have shown that a vaccine based on alphavirus replicon particles (VRP) activates strong cellular and humoral immunity to tyrosinase-related protein-2 (TRP2) melanoma antigen, providing prophylactic and therapeutic effects in stringent mouse models. Here, we report that the immunogenicity and efficacy of this vaccine is increased in combination with either antagonist anti-CTL antigen-4 (CTLA-4)  ...[more]

Similar Datasets

| S-EPMC2744093 | biostudies-literature
| S-EPMC2888770 | biostudies-literature
| S-EPMC3393363 | biostudies-literature
| S-EPMC1383499 | biostudies-literature
| S-EPMC5079404 | biostudies-literature
| S-EPMC2937034 | biostudies-literature
| S-EPMC7918982 | biostudies-literature
| S-EPMC5609554 | biostudies-literature
| S-EPMC228391 | biostudies-literature